Navigation Links
Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
Date:10/27/2008

n dial (877) 356-5706 or (706) 643-0580 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com. A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (800) 642-1687 or (706) 645-9291, access code 69576563, through October 30, 2008. This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Use of Non-GAAP Financial Measures

To supplement its financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share. This non-GAAP financial presentation is not a measurement of performance under GAAP in the United States of America. Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assi
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
2. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
9. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
10. Aware, Inc. Reports Third Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Seahorse Bioscience, the industry leader in ... of XF Technology which is increasingly being adopted ... the links between mitochondrial function and disease are ... rapidly.   Recently, 12 peer-reviewed publications ... (NPG) featuring XF Technology, including Nature, Nature Genetics, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... OF PRUSSIA, Pa. , July 28, 2015 /PRNewswire/ ... U.S. Food and Drug Administration has accepted for review ... investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment ... met all primary endpoints. Hemophilia ... deficient or defective factor VIII; nearly all affected patients ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... John Wagner, M.D., recognized as,a leader in the field ... at CORD:USE Cord Blood Bank. Dr. Wagner,s extensive experience ... provide a,significant contribution to CORD:USE., "We,re honored and ... team," says Edward Guindi, M.D., President and CEO of,CORD:USE ...
... To Draw Attention To ,The Sneak Thief of Sight, ... to combat one of the,main causes of blindness around ... Patient Organization have announced the first annual,World Glaucoma Day, ... will be marked,by awareness and educational events organized by ...
... In,conjunction with QIAGEN,s Fourth Quarter and Year End 2007 Earnings,release, ... be,broadcast live over the Internet on Tuesday, February 12, 2008 at ... and Roland,Sackers, Chief Financial Officer., What: ... and ...
Cached Biology Technology:CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 2CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board 3World Glaucoma Day Set for March 6th 2QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web 2
(Date:7/8/2015)... , July 8, 2015 The ... as this summer,s must have products such as wearables, smart ... as popularity for biometrics based devices continues to rapidly grow.  ... Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: GOOG ... FIT ), GoPro, Inc. (NASDAQ: GPRO ) and ...
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... one of the detrimental effects of climate change, may receive ... research by a team of scientists recording the long-term recovery ... that coral reefs are very resilient and can bounce back ... or so of pristine conditions," says Robert van Woesik, one ...
... baby is doing what other babies her age are doing ... she loves to dance." , Lolita Harding is describing her ... large part to a thymus transplant she received at Duke ... immune system. Dave'yana was the 31st baby to receive such ...
... did the hearing of dinosaurs compare to that of present-day ... conditions in office cubicles" How can sound waves diagnose ... be addressed at the 153rd Meeting of the Acoustical Society ... 2007 in Salt Lake City. Most sessions will be ...
Cached Biology News:Palau's coral reefs show differential habitat recovery following the 1998 bleaching event 2Thymus transplants gives hope to babies with fatal immune disease 2Thymus transplants gives hope to babies with fatal immune disease 3Dinosaur hearing, listening to muscle noise, quieter cubicles 2Dinosaur hearing, listening to muscle noise, quieter cubicles 3Dinosaur hearing, listening to muscle noise, quieter cubicles 4Dinosaur hearing, listening to muscle noise, quieter cubicles 5Dinosaur hearing, listening to muscle noise, quieter cubicles 6Dinosaur hearing, listening to muscle noise, quieter cubicles 7Dinosaur hearing, listening to muscle noise, quieter cubicles 8Dinosaur hearing, listening to muscle noise, quieter cubicles 9Dinosaur hearing, listening to muscle noise, quieter cubicles 10Dinosaur hearing, listening to muscle noise, quieter cubicles 11Dinosaur hearing, listening to muscle noise, quieter cubicles 12Dinosaur hearing, listening to muscle noise, quieter cubicles 13
...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Biology Products: